Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Research And Development Expense of $2.62 million for the year ending 2025.
- ADIAL PHARMACEUTICALS, INC. showed a decrease of -18.9% in Research And Development Expense from 2024 to 2025.
- This data is from ADIAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $57.9 thousand | Q3 2017: $27.8 thousand | Q1 2018: $55.5 thousand | Q2 2018: $76.9 thousand | Q3 2018: $188.4 thousand | Q1 2019: $686.9 thousand | Q2 2019: $1.21 million | Q3 2019: $864.3 thousand | Q1 2020: $1.06 million | Q2 2020: $888.0 thousand | Q3 2020: $1.85 million | Q1 2021: $2.05 million | Q2 2021: $2.32 million | Q3 2021: $1.69 million | Q1 2022: $596.3 thousand | Q2 2022: $680.0 thousand | Q3 2022: $696.1 thousand | Q1 2023: $365.6 thousand | Q2 2023: $429.9 thousand | Q3 2023: $207.1 thousand | Q1 2024: $454.3 thousand | Q2 2024: $1.01 million | Q3 2024: $1.03 million | Q1 2025: $746.9 thousand | Q2 2025: $732.3 thousand | Q3 2025: $521.1 thousand.
- Over the full 9 years of available data (2017 to 2025), ADIAL PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 1,338.5%.
- Historical annual values: Fiscal year 2025: $2.62 million | Fiscal year 2024: $3.23 million | Fiscal year 2023: $1.27 million | Fiscal year 2022: $1.95 million | Fiscal year 2021: $8.40 million | Fiscal year 2020: $5.85 million | Fiscal year 2019: $3.97 million | Fiscal year 2018: $368.5 thousand | Fiscal year 2017: $182.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: